Human Recombinant Monoclonal SPIKE antibody. Suitable for I-ELISA, WB and reacts with SARS-CoV-2 samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
I-ELISA | WB | |
---|---|---|
SARS-CoV-2 | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species SARS-CoV-2 | Dilution info 1/500 | Notes - |
Human Recombinant Monoclonal SPIKE antibody. Suitable for I-ELISA, WB and reacts with SARS-CoV-2 samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
This human monoclonal chimeric antibody has been engineered from a RabMAb parent antibody (Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] ab283942). By necessity, some rabbit sequence is retained as part of the variable domain. When multiplexing with other rabbit-derived antibodies, using cross absorbed Fc-reactive secondary antibodies are recommended.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active, His tagged) (Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) ab273068) at 0.2 ug
Lane 2: Recombinant SARS-COV-2 NSP2 protein (His tagged) at 0.2 ug
Performed under reducing conditions.
Observed band size: 135 kDa.
False colour image of Western blot: Rabbit monoclonal [EPR24852-116] to SARS-CoV-2 Spike Glycoprotein S1 - Human IgG1 (Chimeric), ab323000 staining at 1/500 dilution, shown in black; Mouse Monoclonal 6X His tag® (Anti-6X His tag® antibody [HIS.H8] ab18184) loading control staining at 1/1000 dilution, shown in red. In Western blot, ab323000 was shown to bind specifically to SARS-CoV-2 spike glycoprotein S1. Samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat Anti-Human IgG Fc (HRP) preadsorbed (Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624) at 1:10000 and Goat anti-Mouse IgG H&L 680RD at 1:20000.
Blocking buffer: 3% milk in TBS-0.1% Tween® 20 (TBS-T).
Exposure time: 30 Sec.
All lanes: Western blot - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - Human IgG1 (Chimeric) (ab323000) at 1/500 dilution
Lane 1: Western blot - Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) (Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) ab273068) at 0.2 µg
Lane 2: Recombinant SARS-COV-2 NSP2 protein (His tagged) at 0.2 µg
Lanes 1 - 2: Western blot - Goat Anti-Human IgG Fc (HRP) preadsorbed (Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624) at 1/10000 dilution
Lanes 1 - 2: Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Observed band size: 135 kDa
Exposure time: 30s
Indirect ELISA showing primary antibody ab323000 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera) ab272106) and Recombinant human coronavirus SARS spike glycoprotein (Tagged, Recombinant Human coronavirus SARS spike glycoprotein (Tagged) ab270844) at 1000 ng/ml. Binding of ab323000 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Human IgG Fc (HRP) preadsorbed (Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624) was used at 1:5000.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com